Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 3/20 | 0.50 |
| ▸ | AGXT | P21549 | 2/20 | 0.50 |
| ▸ | CHRM3 | P20309 | 4/20 | 0.46 |
| ▸ | MAOB | P27338 | 6/20 | 0.41 |
| ▸ | APP | P05067 | 1/20 | 0.41 |
| ▸ | GBA1 | P04062 | 1/20 | 0.41 |
| ▸ | UGCG | Q16739 | 1/20 | 0.41 |
| ▸ | GBA2 | Q9HCG7 | 1/20 | 0.41 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.41 |
| ▸ | KCNH3 | Q9ULD8 | 1/20 | 0.41 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.40 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.40 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.40 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ethylene Glycol SCHEMBL5570418 | 0.98 | IDO1 (0.48) | IDO1AGXTCHRM3MAOBAPP | |
| SCHEMBL13602773 | 0.89 | TSHR (0.47) | IDO1CHRM3PTPN2PTPN1PTPN6 | |
| SCHEMBL10853302 | 0.88 | IDO1 (0.47) | IDO1AGXTCHRM3MAOBAPP | |
| SCHEMBL10458653 | 0.84 | IDO1 (0.52) | IDO1AGXTMAOBAPP | |
| SCHEMBL1008118 | 0.84 | GBA1 (0.49) | IDO1AGXTCHRM3MAOBAPP | |
| SCHEMBL14273420 | 0.82 | TSHR (0.41) | IDO1CHRM3PTPN2PTPN1PTPN6 | |
| SCHEMBL7939618 | 0.82 | CA2 (0.52) | IDO1APP | |
| SCHEMBL7888039 | 0.81 | IDO1 (0.64) | IDO1AGXTMAOBAPPNR4A2 | |
| SCHEMBL321367 | 0.81 | TAAR1 (0.45) | IDO1AGXTMAOBKCNH3 | |
| SCHEMBL4049581 | 0.80 | IDO1 (0.52) | IDO1AGXTMAOBAPPNR4A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10478423-B2 | Substituted indazole derivatives active as kinase inhibitiors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2019-11-19 | — | — | US | disclosed |
| US-20180289672-A1 | SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITIORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2018-10-11 | — | — | US | disclosed |
| US-10028934-B2 | Substituted indazole derivatives active as kinase inhibitiors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2018-07-24 | — | — | US | disclosed |
| US-9597317-B2 | Substituted indazole derivatives active as kinase inhibitiors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2017-03-21 | — | — | US | disclosed |
| EP-2707359-B1 | SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES SRL (IT) | 2016-11-30 | — | — | EP | disclosed |
| US-20160311776-A1 | SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITIORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2016-10-27 | — | — | US | disclosed |
| US-20160310465-A1 | SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITIORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2016-10-27 | — | — | US | disclosed |
| EP-2570128-B1 | Muscarinic acetylcholine receptor antagonists | GLAXO GROUP LTD (GB) | 2016-08-10 | — | — | EP | disclosed |
| US-9408850-B2 | Substituted indazole derivatives active as kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2016-08-09 | — | — | US | disclosed |
| US-20160002220-A1 | MUSCARINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS | GLAXO GROUP LTD (GB) | 2016-01-07 | — | — | US | disclosed |
| EP-1144408-B1 | SUBSTITUTED 1-(PIERIDIN-4-YL)-3-(ARYL) ISOTHIOUREAS THEIR PREPARATION AND THERAPEUTIC APPLICATION | PF MEDICAMENT (FR) | 2002-09-25 | — | — | EP | disclosed |
| EP-1144408-A1 | SUBSTITUTED 1-(PIERIDIN-4-YL)-3-(ARYL) ISOTHIOUREAS THEIR PREPARATION AND THERAPEUTIC APPLICATION | PIERRE FABRE MEDICAMENT (FR) | 2001-10-17 | — | — | EP | disclosed |
| WO-2000043391-A1 | SUBSTITUTED 1-(PIERIDIN-4-YL)-3-(ARYL) ISOTHIOUREAS THEIR PREPARATION AND THERAPEUTIC APPLICATION | PIERRE FABRE MEDICAMENT (FR) | 2000-07-27 | — | — | WO | disclosed |
| US-4584396-A | Substituted phenoxypropionates and herbicidal compositions | NIHON TOKUSHU NOYAKU SEIZO K.K. (JP) | 1986-04-22 | — | — | US | disclosed |
| EP-0068260-B1 | SUBSTITUTED PHENOXYPROPIONATES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS HERBICIDES | NIHON TOKUSHU NOYAKU SEIZO K.K. (JP) | 1986-03-05 | — | — | EP | disclosed |
| EP-0086392-B1 | HERBICIDAL AGENT CONTAINING METAMITRON IN COMBINATION WITH CERTAIN PHENOXYPROPIONIC-ACID ESTERS | BAYER AG (DE) | 1985-08-21 | — | — | EP | disclosed |
| US-4441913-A | PRE- AND POST-EMERGENCE | NIHON TOKUSHU NOYAKU SEIZO K.K. (JP) | 1984-04-10 | — | — | US | disclosed |
| EP-0086392-A1 | Herbicidal agent containing metamitron in combination with certain phenoxypropionic-acid esters | BAYER AG (DE) | 1983-08-24 | — | — | EP | disclosed |
| EP-0084819-A2 | Herbicidal agents containing methabenzthiazuron in combination with certain phenoxypropionic acid esters | BAYER AG (DE) | 1983-08-03 | — | — | EP | disclosed |
| EP-0068260-A2 | Substituted phenoxypropionates, process for their preparation and their use as herbicides | NIHON TOKUSHU NOYAKU SEIZO K.K. (JP) | 1983-01-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160002220-A1 | MUSCARINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS | CHRM3, CHRNG, CHRM2 | IDO1 2263/4885AGXT 3619/4885CHRM3 1/4885 |
| US-20160310465-A1 | SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITIORS | MAP3K20, MAP3K1, MAP3K5 | IDO1 871/4885AGXT 3636/4885CHRM3 4280/4885 |
| US-10028934-B2 | Substituted indazole derivatives active as kinase inhibitiors | MAP3K20, MAP3K1, MAP3K5 | IDO1 871/4885AGXT 3636/4885CHRM3 4280/4885 |
| US-20160311776-A1 | SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITIORS | MAP3K20, MAP3K1, MAP3K5 | IDO1 871/4885AGXT 3636/4885CHRM3 4280/4885 |
| US-10478423-B2 | Substituted indazole derivatives active as kinase inhibitiors | MAP3K20, MAP3K1, MAP3K5 | IDO1 871/4885AGXT 3636/4885CHRM3 4280/4885 |
| US-20180289672-A1 | SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITIORS | MAP3K20, MAP3K1, MAP3K5 | IDO1 871/4885AGXT 3636/4885CHRM3 4280/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.